Literature DB >> 26984667

Outcome Predictors in Prosthetic Joint Infections--Validation of a risk stratification score for Prosthetic Joint Infections in 120 cases.

Matthias D Wimmer, Thomas M Randau, Max J Friedrich, Milena M Ploeger, Jan Schmolder, Andreas C Strauss, Peter H Pennekamp, Patrick Vavken, Sascha Gravius.   

Abstract

Prosthetic joint infections are a major challenge in total joint arthroplasty, especially in times of accumulating drug resistancies. Even though predictive risk classifications are a widely accepted tool to define a suitable treatment protocol a classification is still missing considering the difficulty in treating the -causative pathogen antibiotically. In this study, we present and evaluate a new predictive risk stratification for prosthetic joint infections in 120 cases, treated with a two-stage exchange. Treatment outcomes in 120 patients with proven prosthetic joint infections in hip and knee prostheses were regressed on time of infection, systemic risk factors, local risk factors and the difficulty in treating the causing pathogen. The main outcome variable was "definitely free of infection" after two years as published. Age, gender, and BMI were included as covariables and analyzed in a logistic regression model. 66 male and 54 female patients, with a mean age at surgery of 68.3 years±12.0 and a mean BMI of 26.05±6.21 were included in our survey and followed for 29.0±11.3 months. We found a significant association (p<0.001) between our score and the outcome parameters evaluated. Age, gender and BMI did not show a significant association with the outcome. These results show that our score is an independent and reliable predictor for the cure rate in prosthetic joint infections in hip and knee prostheses treated within a two-stage exchange protocol. Our score illustrates, that there is a statistically significant, sizable decrease in cure rate with an increase in score. In patients with prosthetic joint infections the validation of a risk score may help to identify patients with local and systemic risk factors or with infectious organisms identified as "difficult to treat" prior to the treatment or the decision about the treatment concept. Thus, appropriate extra care should be considered and provided.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26984667

Source DB:  PubMed          Journal:  Acta Orthop Belg        ISSN: 0001-6462            Impact factor:   0.500


  5 in total

1.  Pre-operative intra-articular deep tissue sampling with novel retrograde forceps improves the diagnostics in periprosthetic joint infection.

Authors:  Matthias D Wimmer; Milena M Ploeger; Max J Friedrich; Thomas Hügle; Sascha Gravius; Thomas M Randau
Journal:  Int Orthop       Date:  2017-01-14       Impact factor: 3.075

2.  Fluid collection bags pose a threat for bacterial contamination in primary total hip arthroplasty: a prospective, internally controlled, non-blinded trial.

Authors:  M M Ploeger; C Jacobs; M Gathen; E Kaup; T M Randau; M J Friedrich; G T Hischebeth; M D Wimmer
Journal:  Arch Orthop Trauma Surg       Date:  2018-06-11       Impact factor: 3.067

3.  No differences in short-term outcomes between patients with anaerobic and aerobic culture positive prosthetic joint infection.

Authors:  Sravya Vajapey; Daniel Lynch; Mengnai Li
Journal:  J Clin Orthop Trauma       Date:  2020-03-31

4.  Use of Common Inflammatory Markers in the Long-Term Screening of Total Hip Arthroprosthesis Infections: Our Experience.

Authors:  Gabriele Falzarano; Antonio Piscopo; Predrag Grubor; Giuseppe Rollo; Antonio Medici; Valerio Pipola; Michele Bisaccia; Auro Caraffa; Elizabeth Mary Barron; Francesco Nobile; Raffaele Cioffi; Luigi Meccariello
Journal:  Adv Orthop       Date:  2017-08-23

5.  One- and two-stage surgical revision of peri-prosthetic joint infection of the hip: a pooled individual participant data analysis of 44 cohort studies.

Authors:  Setor K Kunutsor; Michael R Whitehouse; Ashley W Blom; Tim Board; Peter Kay; B Mike Wroblewski; Valérie Zeller; Szu-Yuan Chen; Pang-Hsin Hsieh; Bassam A Masri; Amir Herman; Jean-Yves Jenny; Ran Schwarzkopf; John-Paul Whittaker; Ben Burston; Ronald Huang; Camilo Restrepo; Javad Parvizi; Sergio Rudelli; Emerson Honda; David E Uip; Guillem Bori; Ernesto Muñoz-Mahamud; Elizabeth Darley; Alba Ribera; Elena Cañas; Javier Cabo; José Cordero-Ampuero; Maria Luisa Sorlí Redó; Simon Strange; Erik Lenguerrand; Rachael Gooberman-Hill; Jason Webb; Alasdair MacGowan; Paul Dieppe; Matthew Wilson; Andrew D Beswick
Journal:  Eur J Epidemiol       Date:  2018-04-05       Impact factor: 8.082

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.